Intracellular and Extracellular MicroRNAs in Breast Cancer

Abstract

BACKGROUND Successful treatment of breast cancer is enhanced by early detection and, if possible, subsequent patient-tailored therapy. Toward this goal, it is essential to identify and understand the most relevant panels of biomarkers, some of which may also have relevance as therapeutic targets. METHODS We critically reviewed published literature on microRNAs (miRNAs) as relevant to breast cancer. SUMMARY Since the initial recognition of the association of miRNAs with breast cancer in 2005, studies involving cell lines, in vivo models, and clinical specimens have implicated several functions for miRNAs, including suppressing oncogenesis and tumors, promoting or inhibiting metastasis, and increasing sensitivity or resistance to chemotherapy and targeted agents in breast cancer. For example, miR-21 is overexpressed in both male and female breast tumors compared with normal breast tissue and has been associated with advanced stage, lymph node positivity, and reduced survival time. miR-21 knock-down in cell-line models has been associated with increased sensitivity to topotecan and taxol in vitro and the limitation of lung metastasis in vivo. Furthermore, the discovery of extracellular miRNAs (including miR-21), existing either freely or in exosomes in the systemic circulation, has led to the possibility that such molecules may serve as biomarkers for ongoing patient monitoring. Although additional investigations are necessary to fully exploit the use of miRNAs in breast cancer, there is increasing evidence that miRNAs have potential not only to facilitate the determination of diagnosis and prognosis and the prediction of response to treatment, but also to act as therapeutic targets and replacement therapies.

MicroRNAs as Regulators of Signal Transduction in Urological Tumors

“…MicroRNAs (miRNAs or miRs) 5 are short noncoding RNAs with lengths of approximately 19 -22 nucleotides. The first discovery of an miRNA, which occurred in 1993, was of an miRNA in the nematode Caenorhabditis elegans.…”

Modularized Extracellular Vesicles: The Dawn of Prospective Personalized and Precision Medicine

“…In addition to studies showing that EVs are characterized by specific membrane proteins,29 the nucleic acid contents of C‐EVs in the plasma/serum from malignant tumor patients are also markedly different than those from healthy controls, indicating that the specific nucleic acid content in C‐EVs should be the focus of greater attention in the search for new tumor biomarkers 30, 31. Recently, EVs have come to be considered effective diagnostic and predictive tools for patients suffering from malignant tumors, such as breast and prostate cancers 32, 33. In addition to tumors, EVs show potential in the diagnosis of infectious diseases and even in the assessment of disease progression 34, 35, 36…”

Prognostic Significance of Metastasis-Related MicroRNAs in Early Breast Cancer Patients with a Long Follow-up

“…An important focus of current breast cancer research is to increase our understanding of the biology of the metastatic process and to identify panels of biomarkers that may help in early diagnosis and the determination of prognosis and/or the prediction of treatment response, ultimately contributing to more favorable patient outcomes (1 ).…”